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Edited by Angel NebredaAbstract Recent work has shown that the LKB1 tumour sup-
pressor protein kinase phosphorylates and activates protein ki-
nases belonging to the AMP activated kinase (AMPK)
subfamily. In this study, we identify the sucrose non-fermenting
protein (SNF1)-related kinase (SNRK), a largely unstudied
AMPK subfamily member, as a novel substrate for LKB1. We
demonstrate that LKB1 activates SNRK by phosphorylating
the T-loop residue (Thr173), and that the LKB1 regulatory sub-
units STRAD and MO25 are required for LKB1 to activate
SNRK. We ﬁnd that SNRK is not active when expressed in
HeLa cells that lack expression of LKB1, and its activity is re-
stored by expression of wild type LKB1, but not catalytically
deﬁcient LKB1. We also present evidence that two other
AMPK-related kinases more distantly related to AMPK than
SNRK, namely NIM1 and testis-speciﬁc serine/threonine ki-
nase-1 (TSSK1) are not substrates for LKB1. Tissue distribution
analysis indicates that SNRK protein is mainly expressed in tes-
tis, similar to TSSK isoforms, whereas NIM1 is more widely ex-
pressed. These results provide evidence that SNRK could
mediate some of the physiological eﬀects of LKB1.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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syndrome1. Introduction
LKB1 was originally identiﬁed as a gene mutated in the
inherited Peutz Jeghers Syndrome (PJS), in which subjects
are predisposed to developing benign and malignant tumours
[1,2]. Subsequent work demonstrated that overexpression of
LKB1 in various cell lines induced a G1 cell cycle arrest [3,4]
and that mice lacking one allele of the LKB1 gene developed
tumours similar to those found in PJS in humans (reviewed
in [5]). Genetic analysis in Caenorhabditis elegans [6], Drosoph-
ila [7], Xenopus [8] and mammalian cells [9], also indicated that
LKB1 also plays an important role in regulating cell polarity.
In vivo, LKB1 is complexed to STRAD an inactive pseudo-
kinase [10] and MO25 [11], an armadillo repeat domain scaf-
folding protein [12]. The binding of LKB1 to STRAD and
MO25, localises it in the cell cytosol and activates LKB1 by
a mechanism not involving T-loop phosphorylation [13]. The*Corresponding author. Fax: +44 1382 223778.
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AMP activated protein kinase (AMPK) [14–16], which func-
tions as a regulator of cellular energy charge [17]. LKB1 com-
plexed to STRAD and MO25 phosphorylates the T-loop Thr
residue of AMPK (Thr172), leading to activation of this en-
zyme. Further evidence that LKB1 is a key regulator of
AMPK in cells, comes from the ﬁnding that AMPK cannot
be activated in LKB1 knockout ﬁbroblasts or HeLa cells
which do not express LKB1, in response to a variety of treat-
ments that activate AMPK in LKB1 expressing cells.
Inspection of the human genome indicates that in addition
to the 2 isoforms of AMPK, 12 other less studied kinases
(MARK1, MARK2, MARK3, MARK4, QIK, QSK, SIK,
NUAK1, NUAK2, BRSK1, BRSK2, and MELK), are highly
related to AMPK (Fig. 1A). Apart from MELK, which autop-
hosphorylates its own T-loop residue, LKB1 complexed to
STRAD and MO25, phosphorylated the T-loop Thr residue
of the other members of the AMPK-related kinases, resulting
in activation of these enzymes [18]. Moreover, the AMPK-
related kinases activated by LKB1 possessed vastly lower
activity in LKB1-deﬁcient cell lines compared to LKB1-
expressing cells, providing genetic evidence that these enzymes
are indeed physiological substrates of LKB1 [18].
Examination of the human kinome [19] shows that there are
eight other largely unstudied kinases (NIM1, SNRK, TSSK1,
TSSK2, TSSK3, TSSK4, SSTK, and HUNK), on the same
branch as AMPK on the human kinome tree (see Fig. 1A).
Sequence analysis of these enzymes indicates that they are less
related to AMPK than the AMPK-related enzymes that have
previously been shown to be substrates for LKB1. Neverthe-
less, alignment of the T-loop sequences of these enzymes, indi-
cate that they possess a Thr-residue located at an identical
position to the T-loop of AMPK subfamily kinases phosphor-
ylated by LKB1, and many of the surrounding residues are
also conserved (Fig. 1A). This suggests that LKB1 might also
phosphorylate these enzymes and in this study, we provide
evidence that one of these enzymes, namely, the sucrose non-
fermenting related kinase (SNRK) is a substrate for LKB1.2. Materials and methods
2.1. Materials
Protease-inhibitor cocktail tablets and sequencing grade trypsin
were obtained from Roche; P81 phosphocellulose paper was from
Whatman; [c-32P]ATP, glutathione–sepharose, protein G–sepharose
were purchased from Amersham Biosciences. All peptides were syn-
thesised by Dr. Graham Bloomberg at the University of Bristol. Theblished by Elsevier B.V. All rights reserved.
Fig. 1. Activation of SNRK by LKB1. (A) Dendrogram and alignment of the T-loop sequences of AMPK subfamily protein kinases [19]. The T-loop
Thr residue is marked with an asterisk and the 2 Leu is marked with an ﬂ. The identical residues are shaded black and the conserved residues in
grey. (B) Wild-type (WT) SNRK, SNRK[T173A] (T/A) or SNRK[T173E] (T/E), were incubated in the presence or absence of the
LKB1:STRAD:MO25 complex in the presence of Mg2+ and ATP. At the indicated time points SNRK activity was quantiﬁed utilising the
AMARA peptide and the results are expressed as speciﬁc activities. (C) Wild-type NIM1, NIM1[T229A] (T/A) or NIM1[T229E] (T/E) was incubated
in the presence or absence of LKB1:STRAD:MO25 complex as in (B). After 30 min, the activity of the NIM1 towards the AMARA peptide was
quantiﬁed. (D) Similarly, Wild-type TSSK1, TSSK1[T174A] (T/A) or TSSK1[T174E] (T/E) was incubated either in the absence or presence of
LKB1:STRAD:MO25 complex. After 30 min, the activity of the TSSK1 was quantiﬁed employing the AMARA peptide as a substrate. Results shown
are means ± S.D. of assays carried out in duplicate and representative of three independent experiments.
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appropriate antigen: SNRK (residues 1–20 of human SNRK) and
NIM1 (residues 1–28 of human NIM1). Secondary antibodies coupled
to horseradish peroxidase were from Pierce. Immortalised LKB1+/+
and LKB1/ mouse embryonic ﬁbroblast cells from E9.5 kindly pro-
vided to us by Tomi P. Ma¨kela¨ and co-workers [14], have been previ-
ously described.2.2. General methods
Tissue culture, transfection, immunoblotting, restriction enzyme di-
gests, DNA ligations, and other recombinant DNA procedures were
performed using standard protocols. All mutagenesis were carried
out using the Quick-Change site-directed mutagenesis method (Strata-
gene). DNA constructs used for transfection were puriﬁed from Esch-
erichia coliDH5a using Qiagen plasmid Mega or Maxi kit according to
the manufacturers protocol. All DNA constructs were veriﬁed by
DNA sequencing, which was performed by The Sequencing Service,
School of Life Sciences, University of Dundee, Scotland, UK, using
DYEnamic ET terminator chemistry (Amersham Biosciences) on Ap-
plied Biosystems automated DNA sequencers.
2.3. Buﬀers
Lysis Buﬀer contained 50 mM Tris/HCl, pH 7.5, 1 mM EGTA,
1 mM EDTA, 1% w/v Triton-X 100, 1 mM sodium orthovanadate,
10 mM sodium-b-glycerophosphate, 50 mM sodium ﬂuoride, 5 mM
sodium pyrophosphate, 0.27 M sucrose, 0.1% v/v 2-mercaptoethanol,and complete proteinase inhibitor cocktail (one tablet/50 ml). Buﬀer
A contained 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, and 0.1% v/v
2-mercaptoethanol.
2.4. Cloning of SNRK, TSSK1, and NIM1
The full length coding region of human SNRK cDNA (NCBI Acc
NM_017719) containing a 5 0 HA tag sequence were ampliﬁed from
overlapping IMAGE consortium EST clone 813590 and 6189654 using
primers 5 0-gcgaattctacccatacgatgtgccagattacgccgcaggatttaagcgagggtat-
gatgg-3 0 and 5 0-cggaattctcagatgacatggcaacagctggc-3 0. The resulting
PCR product was ligated into pCR2.1-TOPO vector (Invitrogen),
sequenced, and subcloned as an EcoR1–EcoR1 insert into the
pGEX6P-1 expression vector. Full length SNRK with 5 0 HA tag
sequence was ampliﬁed from the pCR2.1-TOPO clone using primers
that incorporated Not1 sites at the 5 0 and 3 0 ends for subcloning into
the pEBG2T expression vector as aNot1/Not1 insert. The coding region
of human NIM1 cDNA (NCBI Acc NM_153361) with an N-terminal
HA tag was ampliﬁed from IMAGE consortium EST 4797792 using
primers 1. 5 0-actagtgccaccatgtacccatacgatgtgccagattacgccactgcagtgta-
tatgaatggaggtggc-3 0 and 2. 5 0-actagttttataaaatcgagcaaaatttggatgtgtg-
3 0. The resulting PCR product was ligated into pCR2.1-TOPO vector
sequenced and subcloned as a Spe1–Spe1 insert into pEBG2T and
Spe1-modiﬁed pGEX6P-1 expression vectors. The coding region of hu-
man TSSK1 cDNA (NCBI Acc NM_032028.2) with an N-terminal HA
tag was ampliﬁed from IMAGE consortium EST 5298216 using prim-
ers 1. 5 0-ggatccgccaccatgtacccatacgatgtgccagattacgccgatgacgctgctg-
tcctcaagcgacgagg-3 0 and 2. 5 0-gcggccgctcactgggcccgcgtctctggaggctg-3 0.
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and subcloned as a BamH1–Not1 insert into pGEX6P-1 and pEBG2T
expression vectors.
2.5. Expression and puriﬁcation of AMPK-related kinases in E: coli
The pGEX constructs of the full-length wild-type or mutant forms
of GST-HA tagged AMPK-related kinases were transformed in E. coli
BL21 cells. One litre cultures were grown at 37 C in LB broth supple-
mented with 100 lg/ml ampicillin and induced at an OD600 of 0.8 with
100 lM IPTG. Cultures were incubated for a further 16 h at 26 C be-
fore harvesting by centrifugation at 4000 · g at 4 C for 30 min. En-
zymes were puriﬁed by glutathione–sepharose aﬃnity puriﬁcation as
described previously [18].
2.6. Activation of SNRK by LKB1
1–2 lg of E. coli-expressed GST-SNRK (or GST-NIM1 or GST-
TSSK1), was incubated with or without 0.3 lg LKB1 in buﬀer A con-
taining 5 mM Mg-acetate and 0.1 mM ATP in a ﬁnal volume of 20 ll.
After incubation at 30 C for the times indicated, 5 ll of the incubation
mix was quenched in 25 ll of ice-cold buﬀer A containing 2 mM
EDTA. The activities of the quenched AMPK-related kinase were
determined by adding 20 ll of 10 mM Mg-acetate, 0.1 mM [c-32P]
ATP, and 200 lM AMARA peptide (AMARAASAAALARRR) as
substrate [18]. After 15 min incubation at 30 C, incorporation of
32P-phosphate into the AMARA peptide substrate was determined
by using the P81 phosphocellulose paper method [20]. One unit of
activity was deﬁned as that which catalysed the incorporation of
1 nmol of 32P into the AMARA peptide.
2.7. Immunoprecipitation and assay SNRK, NIM1 or TSSK1
0.1–1 mg of the indicated cell lysate was incubated at 4 C for 1 h on
a shaking platform with 5 lg of antibody conjugated to 5 ll of protein
G–sepharose. Immunoprecipitates washed twice with Lysis buﬀer con-
taining 0.5 M NaCl, and twice with buﬀer A. Kinase activity of the
immunoprecipitates towards the AMARA peptide was then measured
in a total assay volume of 50 ll as described above.
2.8. Mapping phosphorylation sites
SNRK (10 lg) was incubated for 40 min with 2 lg of wild type
LKB1:STRADa:MO25a in buﬀer A containing 5 mM Mg-acetate
and 100 lM [c-32P]-ATP (5000 cpm/pmol) in a total reaction volume
of 50 ll. The reaction was terminated by adding SDS to a ﬁnal con-
centration of 1% w/v and dithiothreitol to 10 mM and heated at
100 C for 1 min. The sites phosphorylated on SNRK were mapped
using an Applied Biosystems 4700 Proteomics Analyser (MALDI–
TOF–TOF) [18] and on solid-phase Edman degradation on an
Applied Biosystems 494A sequenator of the peptide coupled to
Sequelon-AA membrane (Milligen) [21]. To identify the sites of
phosphorylation on the T-loop of TSSK1, a tryptic peptide digest
of GST-TSSK1 that had been expressed and puriﬁed from E. coli
was analysed by electrospray mass spectrometry on a Q-TOF2
(Waters) electrospray mass spectrometer. Tandem ms/ms spectral
peak lists were searched using the Mascot search engine (Matrix Sci-
ence) against a local database. Phosphorylation sites predicted from
the Mascot search were validated by manual interpretation of the
ms/ms spectra.3. Results
3.1. Activation of SNRK by LKB1
We initially cloned and attempted to express in E. coli GST
fusion proteins encoding full length human NIM1, SNRK,
TSSK1 and HUNK as representative members of the
AMPK-related kinases that had not been previously tested
as LKB1 substrates. We were able to express soluble NIM1,
SNRK, and TSSK1, but were unable to express a soluble form
of HUNK in E. coli or mammalian 293 cells. We next devel-
oped an assay for NIM1, SNRK, TSSK1 using the AMARA
peptide [22], a substrate for all the AMPK-subfamily kinasestested thus far, which is not directly phosphorylated by the
LKB1:STRAD:MO25 complex [18]. Interestingly, incubation
of SNRK with LKB1:STRAD:MO25 complex and Mg-ATP
resulted in time dependent 5-fold activation of SNRK (Fig.
1B). In contrast, NIM1 (Fig. 1C) and TSSK1 (Fig. 1D) when
expressed in E. coli, were highly active in the absence of LKB1
and their activity not signiﬁcantly increased by incubation with
amounts of LKB1:STRAD:MO25 complex that activated
SNRK.
3.2. Mechanism of activation of SNRK by LKB1
To determine whether LKB1 activated SNRK by phos-
phorylating its T-loop Thr residue (Thr173), this was mu-
tated to either Ala to prevent phosphorylation or Glu to
mimic phosphorylation. Both the SNRK[T173A] and
SNRK[T173E] mutants possessed 2-fold lower activity
than wild-type SNRK in the absence of LKB1 phosphoryla-
tion, and their activity was not elevated following incubation
with LKB1 complex and Mg-ATP (Fig. 1A). A catalytically
inactive point mutant of SNRK that does not autophospho-
rylate, was phosphorylated by LKB1 to a stoichiometry of
0.7 mol of phosphate per mole of SNRK, and mutation of
Thr173 to Ala or Glu prevented phosphorylation of SNRK
by the LKB1 complex (Fig. 2A). The LKB1-phosphorylated
32P-labelled SNRK, was digested with trypsin and the result-
ing peptides separated by chromatography on a C18 column
and a single major 32P-eluting peptide termed P1 was ob-
served (Fig. 2B). Solid phase Edman sequencing (Fig. 2C)
and MALDI–TOF mass spectrometry (Fig. 2D), conﬁrmed
the identity of P1 as the SNRK tryptic T-loop peptide phos-
phorylated at Thr173.
Mutation of the T-loop Thr of NIM1 (Fig. 1C) or TSSK1
(Fig. 1D) to Ala inactivated these enzymes, and the mutants
could not be activated by incubation with LKB1 complex
and Mg-ATP. In contrast, mutation of the T-loop Thr on
NIM1 and TSSK1 to Glu to mimic phosphorylation, restored
catalytic activity to a similar level as that of wild-type enzyme.
Electrospray Q-TOF2 mass spectroscopy analysis of a trypsin
digested TSSK1 puriﬁed from E. coli, revealed that it was
phosphorylated at its T-loop residue (Fig. 2D), indicating that
TSSK1 as was previously shown for MELK [18], can auto-
phosphorylate its T-loop Thr residue.
3.3. Activation of SNRK requires LKB1 catalytic activity as well
as STRAD and MO25
To establish the importance of LKB1 catalytic activity
and the STRAD and MO25 subunits in enabling LKB1 to
activate the SNRK, we expressed wild-type or catalytically
inactive GST-tagged LKB1[D194A], FLAG-tagged STRA-
Da/b and myc-tagged MO25a/b in various combinations in
293 cells, aﬃnity puriﬁed the complexes on glutathione–se-
pharose and tested the complexes for their ability to activate
SNRK (Fig. 3). Heterotrimeric LKB1 complexes containing
a catalytically inactive mutant of LKB1 were unable to acti-
vate SNRK, conﬁrming that LKB1 mediated the activation
of SNRK in this reaction (Fig. 3, compare lanes 6–9 with
lanes 10–13). Non-complexed LKB1 failed to activate
SNRK (Fig. 3, compare lanes 1 and 14). The same result
was obtained with LKB1 that had been co-expressed with
MO25a or MO25b (Fig. 3, lanes 4 and 5), which was as ex-
pected, since these proteins do not interact with LKB1 in
the absence of STRADa/b [11]. LKB1:STRAD complexes
Fig. 2. LKB1 phosphorylates SNRK speciﬁcally at the T-loop. (A)E. coli
expressed kinase inactive SNRK[D158A], SNRK[D158A,T173A] (T/A)
or SNRK[D158A,T173E] (T/E), were incubated with LKB1:STRAD:-
MO25 complex in the presence of Mg2+ and [c-32P]ATP. Phosphory-
lationof the SNRKproteinwas determined following electrophoresis on
a polyacrylamide gel and subsequent autoradiography of the Coomassie
blue-stained bands corresponding to each substrate. Similar results were
obtained in three separate experiments. (B) 32P-labelled catalytically
inactive SNRK [D158A] after phosphorylation with the LKB1:SRA-
Da:MO25a complex, was digested with trypsin and chromatographed
on a C18 column. Fractions containing the major
32P-labelled tryptic
peptide (P1) possessing 64% of the applied 32P-radioactivity are shown.
No other major 32P-labelled peptides were observed in other fractions of
the chromatography. (C) Peptide P1 was subjected to solid-phase
sequencing and 32P-radioactivity was measured after each cycle of
Edman degradation. (D) Peptide P1 was analysed by MALDI–TOF–
TOF mass spectrometry and the deduced amino acid sequence and the
site of phosphorylation was indicated, together with the observed and
theoretical mass. The P1 peptide sequence was deduced as LTT(p)SCG-
SLAY ((p) indicates preceding Thr residue is phosphorylated) in which
the Cys residue was pyridethylated from alkylation with 4-vinylpyridine
prior to digestion. P1 was generated by a mixed tryptic/chymotryptic
cleavage resulting from low level chymotryptic activity in the trypsin
employed. The peptide labelled ‘‘TSSK1’’ is derived froma tryptic digest
of unlabelled TSSK1 that had been expressed and puriﬁed from E. coli
and analysed by electrospray mass spectrometry on a Q-TOF2 as in
Section 2. This peptide encompasses the T-loop of TSSK1 phosphor-
ylated at the Thr residue. The results in (D) are Mass of peptide
calculated fromm/z observed in eitherMALDI–TOF–TOF analysis for
SNRK or electrospray for TSSK1. Abbreviations: (p) indicates preced-
ing Thr residue is phosphorylated.
Fig. 3. Activation of SNRK by LKB1 requires STRAD and MO25. The
indicated combinations of GST-tagged wild-type (WT) LKB1 (lanes 1–
9) or kinase inactive (KI) LKB1[D194A] (lanes 10–13) or GST alone
(lane 14), FLAG-tagged STRADa or STRADb, and myc-tagged
MO25a or MO25b, were co-expressed and aﬃnity puriﬁed on
glutathione–sepharose from 293 cells as described previously [14].
The complexes were assayed for their ability to activate SNRK and
results are expressed as speciﬁc activity employing the AMARA
peptide as substrate. Results shown are means ± S.D. of assays carried
out in duplicate and representative of four independent experiments.
Samples of the incubations were also analysed by Western blotting and
probed using anti-GST to detect LKB1, anti-Flag to detect STRAD
isoforms and anti-myc to detect MO25 isoforms.
1420 M. Jaleel et al. / FEBS Letters 579 (2005) 1417–1423also failed to induce a detectable activation of SNRK (Fig.
3, compare lanes 2 and 3). Heterotrimeric complex contain-
ing LKB1, STRADa or STRADb, and MO25a or MO25bwas required to obtain signiﬁcant activation of SNRK
(Fig. 3, lanes 6–9). As previously reported for AMPKa1
[14] and AMPK-related kinases [18], the LKB1:STRADa:-
MO25a complex activated SNRK most eﬃciently.
3.4. Activation of SNRK in HeLa cells requires LKB1
In order to investigate SNRK activity in cells, we generated
peptide antibodies that detect <1 ng of recombinant SNRK
in an immunoblot analysis and readily immunoprecipitate
SNRK in an active form that had been expressed by transient
transfection in 293 cells (data not shown). Using this anti-
body, we were unable to detect endogenous SNRK protein
or immunoprecipitate detectable SNRK activity in all cell
lines tested, including 293 cells, LKB1/ or LKB1+/+ mouse
embryonic ﬁbroblasts cells or HeLa cells that do not express
LKB1 (data not shown). In order to obtain evidence that
LKB1 regulated SNRK in cells, we overexpressed SNRK
by transient transfection in control HeLa cells that lack
LKB1 as well as HeLa cells that stably express either wild-
type or catalytically inactive LKB1 (Fig. 4). SNRK puriﬁed
from HeLa cells expressing wild-type LKB1 was substantially
more active than SNRK expressed in control HeLa cells lack-
ing LKB1 or HeLa cells expressing catalytically inactive
LKB1 (Fig. 4A).
We also generated a NIM1 peptide antibody, and in con-
trast to SNRK, were readily able to detect, immunoprecipi-
tate and assay endogenously expressed NIM1 in all cells
lines tested. Consistent with the notion that NIM1 is not
regulated by LKB1, NIM1 possessed the same catalytic
activity when immunoprecipitated from control HeLa cells
or cells expressing catalytically active LKB1 (Fig. 4B). We
also observed that NIM1 immunoprecipitated from
Fig. 5. Tissue distribution of SNRK and NIM1. SNRK (A) or NIM1
(B) was immunoprecipitated from 1 mg of the indicated rat tissue
lysates using speciﬁc antibodies as described in Section 2. The
immunoprecipitates were either subjected to an in vitro AMARA
peptide kinase activity or immunoblotted with antibodies recognising
the SNRK (A) or NIM1 (B) proteins. Results of kinase activities are
means ± S.D. of assays carried out in triplicate and representative of
two independent experiments.
Fig. 4. SNRK requires LKB1 to be active in cells. (A) GST-SNRK
was overexpressed in Control HeLa cells () lacking LKB1
expression or HeLa cells stably expressing wild-type (WT) LKB1
or kinase inactive (KI) LKB1[D194A]. Forty-four hours post-
transfection cells were lysed and GST-SNRK aﬃnity puriﬁed from
the cell lysates and its activity quantiﬁed employing the AMARA
peptide as substrate. Cell lysates were immunoblotted with an anti-
HA antibody to detect SNRK or anti-LKB1 was used to detect
LKB1. (B) The activity of endogenous NIM1 immunoprecipitated
from the indicated HeLa cell lysates was determined using the
AMARA peptide as substrate. (C) As in (A) except that TSSK1
was expressed rather than SNRK. Results are shown are
means ± S.D. of 2–4 assays and are representative of two indepen-
dent experiments.
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same activity as that isolated from wild-type LKB1+/+ cells
(MJ & AM, data not shown). We were unable to generate
an antibody recognising TSSK1, but observed that TSSK1
in contrast to SNRK, possessed high basal activity when ex-
pressed in control HeLa cells, which was not further stimu-
lated by overexpression of LKB1 (Fig. 4C).3.5. Tissue distribution of SNRK and NIM1 protein
To investigate the protein distribution of SNRK and
NIM1, we attempted to immunoprecipitate these enzymes
from 9 rat tissues, and subjected these to immunoblot and
AMARA peptide kinase activity analysis. We were only able
to detect SNRK protein and activity in testis extracts (Fig.
5A). In contrast, NIM1 protein could be detected at varying
levels in all tissues, but AMARA peptide kinase activity of
NIM1 immunoprecipitates was most abundant in brain and
testis (Fig. 5B).4. Discussion
SNRK was originally identiﬁed in a PCR-based screen de-
signed to identify novel protein kinases [23]. Subsequent
studies indicated that SNRK mRNA was induced 3-fold
when granule neurons were cultured in low potassium, indi-
cating that it could play a role in regulating survival re-
sponses in these cells [24]. Analysis of SNRK mRNA
suggested that it was expressed in hematopoietic progenitor
cells and several leukemic cell lines [25]. Northern blot anal-
ysis of SNRK mRNA in rat tissues indicated that it was
expressed mainly in brain and testis [24]. Analysis of
rat SNRK mRNA expression in NCBI UniGene
(www.ncbi.nlm.nih.gov), indicates that it is only detected in
testis tissue consistent with the results presented in Fig.
5A. In contrast, analysis of human SNRK mRNA expres-
sion in NCBI UniGene, indicates that it is found in diverse
tissues. Although SNRK mRNA has been detected in Jurkat
cells [25], we have been unable to detect SNRK protein in
these cells using our antibody (MJ data not shown), suggest-
ing that SNRK protein levels may not correlate with mRNA
levels. Our ﬁnding that SNRK is abundant in testis, indi-
cates that it may have similar tissue distribution to the 4 iso-
forms of TSSK, whose mRNA are almost exclusively
expressed in the testis [26–29], and have thus been proposed
1422 M. Jaleel et al. / FEBS Letters 579 (2005) 1417–1423to play a role in regulating spermatogenesis and/or sperm
motility.
Our ﬁnding that TSSK1 is active and phosphorylated at
its T-loop residue when expressed in E. coli, and not further
activated by LKB1 suggests that it is not a substrate for
LKB and is able to autoactivate itself. As the 3 other iso-
forms of TSSK are highly homologous in sequence to
TSSK1 [26], it is likely that these will also not be activated
by LKB1.
Cantley and colleagues have determined the optimal sub-
strate phosphorylation motif for LKB1, employing degener-
ate peptide library screen and found that LKB1 possesses a
strong preference to phosphorylate Thr residues which pos-
sess a Leu residue at the 2 position [16]. Interestingly,
SNRK together with the 13 other AMPK subfamily kinases
that are phosphorylated and activated by LKB1 (AMPKa1,
AMPKa2, NUAK1, NUAK2, BRSK1, BRSK2, QIK, SIK,
QSK, MARK1, MARK2, MARK3 and MARK4), possesses
a Leu residue at the 2 position from the T-loop Thr
(Fig. 1A). In contrast, TSSK1, TSSK2, TSSK3, TSSK4,
SSTK as well as HUNK (hormonally up regulated Neu-
associated kinase [30]) do not possess such a 2 Leu residue
before the T-loop Thr residue, suggesting a reason for why
these proteins may not be LKB1 substrates. Unfortunately,
we were unable to express signiﬁcant levels of HUNK, that
has been suggested contribute to changes in the mammary
gland that occur during pregnancy in response to ovarian
hormones [31]. However, as HUNK is the least related
AMPK subfamily kinase to AMPK and also lacks the 2
Leu residue (Fig. 1A), it may not comprise an LKB1 sub-
strate.
To our knowledge NIM1 has not been previously been
studied and its DNA sequence has only been reported from
human mouse and rat genome sequencing projects. NIM1
possess only 436 amino acids and is thus over 200 residues
shorter in sequence than the other AMPK-related kinases
phosphorylated by LKB1. Interestingly, NIM1 does posses
a Leu residue at the 2 position from the T-loop Thr. How-
ever, as NIM1 expressed in E. coli (Fig. 1C) or HeLa cells
lacking LKB1 (Fig. 4B) is active, it is unlikely to be a phys-
iological substrate for LKB1. The ﬁnding that mutation of
the T-loop Thr residue of NIM1 to Ala, inactivated the en-
zyme, whereas, its mutation to Glu to mimic phosphoryla-
tion restored activity, also suggests that NIM1 activates
itself by autophosphorylating its own T-loop residue. In this
regard, NIM1 is similar to the MELK AMPK-related ki-
nase, which also possesses a Leu residue at the 2 position,
but is capable of autophosphorylating itself at this residue
[18]. It should be noted that although we can detect
NIM1 protein by immunoblot analysis in all rat tissues ana-
lysed, signiﬁcant levels of NIM1 activity following immuno-
precipitation were only observed in brain and testis tissues.
This may indicate that NIM1 is maintained in an inactive
form in tissues such as muscle and adipose tissue (Fig.
5B). Further work is required to establish the physiological
roles of SNRK. In conclusion, we provide evidence that
SNRK is activated by LKB1 and could therefore mediate
cellular eﬀects regulated by LKB1. Moreover, a signiﬁcant
number of inherited forms of PJS do not possess mutations
in the LKB1 gene [32], suggesting that there are other caus-
ative loci for PJS. It would be interesting to test whether
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